The effectiveness of neurofeedback and stimulant drugs in treating AD/HD: Part I. Review of methodological issues

Applied Psychophysiology Biofeedback

Volumn 29, Issue 2, 2004, Pages 95-112

  Rossiter, Thomas ^a  

^a NONE   (United States)

Author keywords

Active treatment control; AD HD; Neurofeedback; Research design; Stimulant drugs

Indexed keywords

CENTRAL STIMULANT AGENT;

AGGRESSION; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; CHILD BEHAVIOR; CONDUCT DISORDER; DEPRESSION; ELECTROENCEPHALOGRAM; EYE MOVEMENT; FEEDBACK SYSTEM; HUMAN; INTERMETHOD COMPARISON; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; REVIEW; STANDARDIZATION; STATISTICAL ANALYSIS; WITHDRAWAL SYNDROME;

ARTIFACTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIOFEEDBACK (PSYCHOLOGY); CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; ELECTROENCEPHALOGRAPHY; EYE MOVEMENTS; HUMANS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 3242808157     PISSN: 10900586     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:APBI.0000026636.13180.b6     Document Type: Review

References (72)

1. Achenbach, T. M., McConaughy, S. H., & Howell, C. T. (1987). Child/adolescent behavioral and emotional problems: Implications of cross-informant correlations for situational specificity. Psychological Bulletin, 101, 213-232.
2. American Academy of Child and Adolescent Psychiatry. (2002). Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Journal of the American Academy of Child and Adolescent Psychiatry, 41(2S), 26S-49S.
3. Anderson, S., & Hauck, W. W. (1983). A new procedure for testing equivalence in comparative bioavailability and other clinical trials. Communications in Statistics -Theory and Methods, 12, 2663-2692.
4. Barkley, R. A. (1977). A review of stimulant drug research with hyperactive children. Journal of Child Psychology and Psychiatry, 18, 137-165.
5. Barkley, R. A. (1990). Attention deficit hyperactivity disorder: A handbook for diagnosis and treatment. New York: Guilford Press.
6. Barkley, R. A. (1991). The ecological validity of laboratory and analogue assessment methods of ADHD symptoms. Journal of Abnormal Child Psychology, 19, 149-178.
7. Barkley, R. A. (1992). Is EEG biofeedback treatment effective for ADHD children? Ch.A.D.D.er Box, pp. 5-11.
8. Barkley, R. A. (1993). Continuing concerns about EEG biofeedback/ neurofeedback. ADHD Report, 1(3), 1-3.
9. Barkley, R. A., & Edwards, G. (1998). Diagnostic Interview, Behavior Rating Scale, and the Medical Examination. In R. A. Barkley (Ed.), Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment (2nd ed., pp. 263-293). New York: Guilford Press.
10. Borkovec, T. D., & Castonguay, L. G. (1998). What is the meaning of empirically supported therapy? Journal of Consulting and Clinical Psychology, 66(1), 136-142.
11. Brown, R. T., Wynne, M. E., Borden, K. A., Clingerman, S. R., Geniesse, R., & Spunt, A. L. (1986). Methylphenidate and cognitive therapy in children with attention deficit disorder. A double-blind trial. Developmental and Behavioral Pediatrics, 7, 163-172.
12. Chambless, D. L., Baker, M. J., Baucaom, D. H., Beutler, L. E., Calhoun, K. S., Crits-Christoph, P., et al. (1998). Update on empirically validated therapies II. The Clinical Psychologist, 51(1), 3-16.
13. Chambless, D. L., & Hollon, S. D. (1998). Defining empirically supported therapies. Journal of Consulting and Clinical Psychology, 66(1), 7-18.
14. Clarke, G. N. (1995). Improving the transition from basic efficacy research to effectiveness studies: Methodological issues and procedures. Journal of Consulting and Clinical Psychology, 63, 718-725.
15. Conoley, C. W., Graham, J. M., Neu, T., Craig, M. C., O'Pry, A., Cardin, S. A., et al. (2001, August). The efficacy of solution focused family therapy with four aggressive and oppositional acting children. Paper presented at the annual meeting of the American Psychological Association, San Francisco.
16. DuPaul, G. J., Barkley, R. A., & Connor, D. E. (1998). Stimulants. In R. A. Barkley (Ed.), Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment (2nd ed., pp. 263-293). New York: Guilford Press.
17. Fitzgerald, R. L. (2001). Statistical reliability of the test of variables of attention. Dissertation Abstracts International, 61(7-B), 3895.
18. Forbes, G. B. (1998). Clinical utility of the Test of Variables of Attention (TOVA) in the diagnosis of attention deficit hyperactivity disorder. Journal of Clinical Psychology, 54, 461-476.
19. Fuchs, T., Birbaumer, N., Lutzenberger, W., Gruzelier, J. H., & Kaiser J. (2003). Neurofeedback treatment for attention-deficit/hyperactivty disorder in children: A comparison with methylphenidate. Applied Psychophysiology and Biofeedback, 28(1), 1-12.
20. Glantz, L. H. (1996). Conducting research with children: Legal and ethical issues. Journal of the American Academy of Child and Adolescent Psychiatry, 35(10), 1283-1291.
21. Gordon, M., & Barkley, R. A. (1998). Tests and observational measures. In R. A. Barkley (Ed.), Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment (2nd ed., pp. 263-293). New York: Guilford Press.
22. Hatch, J. P. (1996). Using statistical equivalence testing in clinical biofeedback research. Biofeedback and Self-Regulation, 21(2), 105-119.
23. Hwang, I. K., & Morikawa, T. (1999). Design issues in noninferiority/equivalence trials. Drug Information Journal, 33, 1205-1218.
24. Kamphaus, R. W., & Frick, P. J. (2002). Clinical assessment of child and and adolescent personality and behavior (2nd ed.). Needham Heights, MA: Allyn & Bacon.
25. Kavale, K. (1982). The efficacy of stimulant drug treatment for hyperactivity: A meta-analysis. Journal of Learning Disabilities, 15, 280-289.
26. Kazdin, A. E. (2003). Research design in clinical psychology (4th ed.). Boston: Allyn & Bacon.
27. Kline, J. P., Brann, C. N., & Loney, B. R. (2002). A cacophony in the brainwaves: A critical appraisal of neurotherapy for attention-deficit disorders. The Scientific Review of Mental Health Practice, 1, 44-54.
28. Klorman, R., Brumaghim, J. T., Fitzpatrick, P. A., & Borgstedt, A. D. (1991). Methylphenidate speeds evaluation processes of attention deficit disorder adolescents during a continuous performance test. Journal of Abnormal Child Psychology, 19, 263-283.
29. La Vaque, T. J., & Rossiter, T. R. (2001). The ethical use of placebo controls in clinical research: The Declaration of Helsinki. Applied Psychophysiology and Biofeedback, 26(1), 23-37.
30. Leark, R. A., Dupuy, T. R., Greenberg, L. M., Corman, C. L., & Kindschi, C. L. (1996). Test of Variables of Attention Professional manual version 7.0. Los Alamitos, CA: Universal Attention Disorders.
31. Leber, P. D. (1989). Hazards of inference: The active control investigation. Epilepsia, 30(Suppl. 1), S57-S63.
32. Li, X., & Wang, Y. (2000). A preliminary application of the Test of Variables of Attention (TOVA) in China. Chinese Mental Health Journal, 14(3), 149-152.
33. Llorente, A. M., Amado, A. J., Voight, R. G., Berretta, M. C., Fraley, J. K., Jensen, C. L., et al. (2001). Internal consistency, temporal stability, and reproducibility of individual index scores of the Test of Variables of attention in children with attention-deficit/hyperactivity disorder. Archives of Clinical Neuropsychology, 16(6), 535-546.
34. Lohr, J., Meunier, S., Parker, L., & Kline, J. P. (2001). Neurotherapy does not qualify as an emprically supported behavioral treatment for psychological disorders. The Behavior Therapist, 24(5), 97-104.
35. Losier, B. J., McGrath, P. J., & Klein, R. M. (1996). Error patterns on the continuous performance test in non-medicated and medicated samples of children with and without ADHD: A meta-analytic review. Journal of Child Psychology and Psychiatry, 37, 971-987.
36. Lubar, J., & Lubar, J. (1999). Neurofeedback assessment and treatment for attention deficit/hyperactivity disorders. In J. R. Evans & A. Abarbanel (Eds.), Introduction to quantitative EEG and neurofeedback (pp. 103-143). San Diego, CA: Academic Press.
37. Lubar, J. F. (1995). Neurofeedback for the management of attention-deficit/hyperactivity disorder. In M. S. Schwartz & Associates (Eds.), Biofeedback: A practitioner's guide (2nd ed., pp. 493-522). New York: Guilford Press.
38. Monastra, V. J., Monastra, D. M., & George, S. (2002). The effects of stimulant therapy, EEG biofeedback, and parenting style on the primary symptoms of attention-deficit/hyperactivity disorder. Applied Psychophysiology and Biofeedback. 27(4), 231-249.
39. MTA Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 56, 1073-1086.
40. O'Leary, K. D., & Borkovec, T. D. (1978). Conceptual, methodological, and ethical problems of placebo groups in psychotherapy research. American Psychologist, 33, 821-830.
41. Ostrander, R., Weinfurt, K. P., Yarnold, P. R., & August, G. J. (1998). Diagnosing attention deficit disorders with the Behavior Asssessment System for Children and the Child Behavior Checklist: Test and construct validity analyses using optimal discriminant classification trees. Journal of Consulting and Clinical Psychology, 66, 660-672.
42. Rapoport, J. L., Buchsbaum, M. S., Weingartner, H., Zahn, T., Ludlow, C., & Mikkelsen, E. J. (1980). Dextroam-phetamine: Its cognitive and behavioral effects in normal and hyperactive boys and normal men. Archives of General Psychiatry, 37, 933-943.
43. Rapoport, J. L., Bucksbaum, M. S., Zahn, T. P., Weingartner, H., Ludow, C., & Mikkelsen, E. J. (1978). Dextroamphetamine: Cognitive and behavioral effects in normal prepuberal boys. Science, 199, 560-563.
44. Reynolds, C. R., & Kamphaus, R. W. (1992). Behavior Assessment System for Children manual. Circle Pines, MN: American Guidance Service.
45. Reynolds, C. R., & Kamphaus, R. W. (2002). The clinician's guide to the Behavior Assessment System for Children. New York: Guilford Press.
46. Riccio, C. A., Reynolds, C. R., & Lowe, P. A. (2001). Clinical applications of continuous performance tests: Measuring attention and impulsive responding in children and adults. New York: Wiley.
47. Riccio, C. A., Waldrop, J. J., Reynolds, C. R., & Lowe, P. A. (2001). Effects of stimulants on the continuous performance test (CPT): Implications for CPT use and interpretation. Journal of Neuropsychiatry and Clinical Neurosciences, 13, 326-335.
48. Rogers, J. L., Howard, K. I., & Vessey, J. T. (1993). Using significance tests to evaluate equivalence between two experimental groups. Psychological Bulletin, 113(3), 553-565.
49. Rossiter, T. R. (1998). Patient directed neurofeedback for AD/HD. Journal of Neurotherapy, 2, 54-64.
50. Rossiter, T. R. (2002). Neurofeedback for AD/HD: A ratio feedback case study and tutorial. Journal of Neurotherapy, 6(3), 9-35.
51. Rossiter, T. R. (2003). The effectiveness of neurofeedback and stimulant drugs in treating AD/HD: Part II. Replication. Manuscript submitted for publication.
52. Rossiter, T. R., & La Vaque, T. J. (1995). A comparison of EEG biofeedback and psychostimulants in treating attention deficit hyperactivity disorders. Journal of Neurotherapy, 1, 48-59.
53. Schuirmann, D. J. (1987). A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Biopharmaceutics, 15(6), 657-680.
54. Selwyn, M. R., Dempster, A. P., & Hall, N. R. (1981). A Bayesian approach to bioequivalence for the 2 x 2 changeover design. Biometrics, 37, 11-21.
55. Spencer, T., Wilens, T., Biederman, J., Faraone, S. V., Ablon, J. S., & Lapey, K. (1995). A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Archives of General Psychiatry, 52, 434-443.
56. Stevens, J. S. (1999). Intermediate statistics: A modern approach (2nd ed.). Mahwah, NJ: Erlbaum.
57. Swartwood, M. O., Swartwood, J. N., Lubar, J. F., Timmermann, D. L., Zimmerman, A. W., & Muenchen, R. A. (1998). Methylphenidate effects on EEG, behavior, and performance in boys with ADHD. Pediatric Neurology, 18(3), 244-250.
58. Temple, R. T., & Ellenberg, S. S. (2000). Placebo-controlled trials and active-controlled trials in the evaluation of new treatments. Annals of Internal Medicine, 133(6), 455-463.
59. Vaughn, M., Riccio, C., Hynd, G., & Hall, J. (1997). Diagnosing ADHD (predominantly inattentive and combined subtypes): Discriminant validity of the Behavior Assessment System for Children (BASC) and the Achenbach Parent and Teacher Rating Scales. Journal of Clinical Child Psychology, 26(4), 349-357.
60. Vitiello, B. (2001). Methylphenidate in the treatment of children with attention-deficit hyperactivity disorder. Canadian Medical Association Journal, 165(11), 1505-1506.
61. Wada, N. Y., Yamashita, Y., Matsuishi, T., Ohtani, Y., & Kato, H. (2000). The Test of Variables of Attention (TOVA) is useful in the diagnosis of Japanese male children with attention deficit hyperactivity disorder. Brain and Development, 22(6), 378-382.
62. Waschbusch, D. A., & Hill, G. P. (2001). Alternative treatments for children with Attention-Deficit/Hyperactivity Disorder: What does the research say? The Behavior Therapist, 24(8), 161-171.
63. Weiss, G., & Hechtman, L. T. (1993). Hyperactive children grown up: ADHD in children, adolescents, and adults (2nd ed.). New York: Guilford Press.
64. Weiss, B., & Weisz, J. R. (1990). The impact of methodological factors on child psychotherapy outcome research: A meta-analysis for researchers. Journal of Abnormal Child Psychology, 18, 639-670.
65. Weisz, J. R., & Weiss, B. (1989). Assessing the effects of clinic-based psychotherapy with children. Journal of Consulting and Clinical Psychology, 57, 741-746.
66. Weisz, J. R., Weiss, B., & Donenberg, G. R. (1992). The lab versus the clinic: Effects of child and adolescent psychotherapy. American Psychologist, 47, 1578-1585.
67. Wender, P. H., Reimherr, F. W., Wood, D., & Ward, M. (1985). A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. American Journal of Psychiatry, 142, 547-552.
68. Westlake, W. J. (1981). Bioequivalence testing - A need to rethink. Biometrics, 37, 591-593.
69. Westlake, W. J. (1988). Bioavailability and bioequivalence of pharmaceutical formulations. In K. E. Peace (Ed.), Biopharmaceutical statistics for drug development (pp. 329-352). New York: Marcel Decker.
70. World Medical Association Declaration of Helsinki. (2000). Ethical principles for medical research involving human subjects. JAMA, 284(23), 3043-3045.
71. Zeiner, P., Bryhn, G., Bjercke, C., Truyen, K., & Strand, G. (1999). Response to methylphenidate in boys with attention-deficit hyperactivity disorder. Acta Paediatrica Scandinavia, 88(3), 298-303.
72. Zimmerman, M., Mattia, J. I., & Posternak, M. A. (2002). Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? American Journal of Psychiatry, 159(3), 469-473.